Bendamustine is a hybrid antimetabolite and alkylating agent offering new therapeutic options for the treatment of non-Hodgkin lymphomas. Hematol Meeting Rep [Internet]. 2009 Jun. 23 [cited 2025 Jun. 20];2(5). Available from: https://journals.pagepress.org/hmr/article/view/749